Results 121 to 130 of about 72,800 (252)

Cytomegalovirus and Epstein-Barr virus infections among Jordanians: seroprevalence and associated factors. [PDF]

BMC Infect Dis
Kofahi HM, Swedan SF, Aljezawi M.
europepmc   +1 more source

Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis. [PDF]

Pediatr Transplant, 2019
Paulsen G, Cumagun P, Mixon E, Fowler K, Feig D, Shimamura M.   +5 more
europepmc   +1 more source

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

Exploring the Link Between Genetic Predictors of Systemic Lupus Erythematosus and Epstein-Barr Virus Infections. [PDF]

Int J Rheum Dis
Piao Y, Li L, An R, Cui D, Cui X, Jiang L, Jin J.   +6 more
europepmc   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study

European Journal of Haematology, Volume 117, Issue 1, Page 210-218, July 2026.
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen, Martin Jensen, Rasmus Rask Kragh Jørgensen, Paw Jensen, Henrik Frederiksen, Dennis L. Hansen, Daniel El Fassi, Morten Nørgaard Andersen, Tarec Christoffer El‐Galaly   +8 more
wiley   +1 more source

Mycobacterium avium Subsp. paratuberculosis and Human Endogenous Retrovirus in Italian Patients With Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS)

Immunology, Volume 178, Issue 3, Page 417-427, July 2026.
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease (CD), is a recognised gastrointestinal disorder. Mycobacterium avium subspecies paratuberculosis (MAP) is implicated in IBD pathogenesis. Persistent exposure and active infections by MAP may contribute to the unsilencing of human endogenous retroviruses (HERV ...
Stefano Ruberto, Alfredo Santovito, Gian P. Caviglia, Marta Noli, Davide Cossu, Davide G. Ribaldone, Demis Pitoni, Simona Frara, Elisa Tribocco, Chiara Rosso, Marta Guriglia, Ilaria Cossu, Pier A. Tovo, Massimiliano Bergallo, Leonardo A. Sechi   +14 more
wiley   +1 more source

Identifying Safeguards Disabled by Epstein-Barr Virus Infections in Genomes From Patients With Breast Cancer: Chromosomal Bioinformatics Analysis. [PDF]

JMIRx Med
Friedenson B.
europepmc   +1 more source

The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity

Immunological Reviews, Volume 340, Issue 1, July 2026.
ABSTRACT Advances in high‐throughput sequencing, single‐cell profiling, and genome engineering have transformed the study of T cell receptors (TCRs), enabling the identification and functional interrogation of antigen‐specific repertoires at an unprecedented scale.
Kilian Schober
wiley   +1 more source

Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience. [PDF]

Ann Hematol, 2020
Zhou L, Gao ZY, Lu DP.
europepmc   +1 more source